Myositis ossificans progressiva, right shoulder
ICD-10 M61.111 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, right shoulder.
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscle tissue, leading to progressive loss of mobility and muscle function. This condition is caused by mutations in the ACVR1 gene, which plays a crucial role in the regulation of bone growth. In patients with MOP, muscle tissue is replaced by bone, particularly after trauma or injury, resulting in stiffness and pain in the affected area. The right shoulder is a common site for this condition, where patients may experience significant muscle weakness and limited range of motion. Diagnosis is typically made through clinical evaluation, imaging studies such as X-rays or MRI, and genetic testing. Management focuses on symptomatic relief, physical therapy, and avoiding trauma to the affected muscles. Surgical intervention may be considered in severe cases, but it carries risks of exacerbating the condition. Understanding the complexities of MOP is essential for accurate coding and appropriate patient management.
Detailed clinical notes on symptoms, physical examination findings, and any imaging or lab results.
Patients presenting with muscle pain and stiffness, particularly after trauma.
Documentation should include family history and any previous episodes of myositis.
Genetic testing results and family pedigree analysis.
Patients with a family history of myositis or unexplained ossification.
Ensure that genetic counseling notes are included in the documentation.
Used for pain management in patients with myositis ossificans.
Document the indication for the procedure and any imaging guidance used.
Rheumatology specialists should ensure that the procedure is justified based on the patient's symptoms.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscle tissue, leading to progressive loss of mobility and muscle function.
Diagnosis is made through clinical evaluation, imaging studies, and genetic testing to confirm mutations in the ACVR1 gene.
Management focuses on symptomatic relief, physical therapy, and avoiding trauma. Surgical intervention may be considered in severe cases.
